News

Study findings revealed statistically significant results at week 4 for the 100-U dose compared to placebo. The 75-U dose, while effective, did not achieve statistical significance.

The data from the phase III EXPAND study indicated to the researchers that this risk reduction obtained with siponimod was substantially isolated from MS relapse.

Chronic traumatic encephalopathy is a neurodegenerative disease that is believed to be a consequence of exposure to repetitive head impacts, including concussions and subconcussive injuries.

In 3 clinical trials including more than 300 patients, the oral solution resulted in significant reductions in seizures for patients with both epileptic conditions.

When and why were the Beers criteria set in place? Learn more in this quiz.

Newly approved medications for various types of pain, generalized myasthenia gravis, and Parkinson disease will be fodder for discussion at AAN 2018. Here’s a brief overview of the therapies the FDA has approved within the past 6 months.

The calcitonin gene-related peptide inhibitor lowered monthly migraine days by ≥50% in 30.3% of patients compared to 13.7% on placebo.

A photographic memory with low resolution images.

Here: the most notable changes in the new AAN guideline on mild cognitive impairment.

This is a unique opportunity for talented early career psychiatrists and neurologists to gain experience in scholarly activities and research.

Using the NCT-504 compound to inhibit cell-signaling activity in PIP4Kγ resulted in an increase in autophagy in connective tissue cells from patients with HD.

Vagus nerve stimulation in conjunction with conventional rehabilitation services more than doubled lasting recovery in forelimb supination and simple motor tasks following a stroke.

What's the link between restrictive anorexia, anorexia nervosa, and binge eating disorder and ASD? This study sheds some light.

Alterations in the gut microbiome may trigger autoimmunity against the CNS, and contribute to the development of neuropsychiatric disorders. How? A recent review offers insights.

The treatment is the first patient-infused subcutaneous formulation of immunoglobulin to gain approval for CIDP.

Epilepsy appears to be the main reason for an increased risk of serious traffic accidents among patients with the disease -not anti-epileptic drugs.

Exposure to monesin has been shown to combat stress by oxidants and free radicals via the protein kinase R-like endoplasmic reticulum kinase/activating transcription factor 4 pathway.

This study points to nitrated nucleosomes as a promising biomarker for distinguishing neuropsychiatric events due to systemic lupus erythematosus from those secondary to other disorders.

The FDA has accepted an application for solriamfetol as a treatment for excessive sleepiness associated with narcolepsy or obstructive sleep apnea, with a PDUFA action date set for December 20, 2018.

Children exposed to antiretrovirals (ARVs) may have worse neurodevelopmental outcomes than children never exposed to ARVs according to a systematic review and meta-analysis.

Which brain regions are potential deep brain stimulation targets for neurological disorders with memory impairment? Take the quiz and learn more.

The goal for the companies is to reach greater levels of anti-tau antibodies in a single treatment that what current weekly or bi-weekly infusions can achieve.

The FDA had accepted a new drug application for the inhaled levodopa therapy for the treatment of OFF period symptoms in patients with Parkinson disease who are taking a carbidopa/levodopa regimen.

The once-daily therapy will be available in 3 doses—129 mg, 193 mg, and 258 mg—giving patients flexibility in regimen setting among the options.

The FDA has expanded the approval for the Trevo clot retrieval device to allow for thrombectomy up to 24 hours after the development of symptoms in patients with acute ischemic stroke.

The perception of good vibes and bad vibes is among the most difficult human experiences to define. The feeling that something “feels right” or that something “just isn’t right” has been attributed to multiple factors.

The injection therapy now has an indication for use in either 40 mg/mL or 20 mg/mL doses, with the lower dose having been approved in June 2015.

In a head-to-head comparison, levetiracetam was shown to increase the rate of infants free of monotherapy failure by 28% more than phenobarbital in pediatric patients with nonsyndromic epilepsy.